BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

Go back to BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
(NASDAQ: BBIO) Delayed: 67.74 +0.19 (0.28%)
Previous Close $67.55    52 Week High $ 
Open $68.04    52 Week Low $ 
Day High $68.79    P/E N/A 
Day Low $67.55    EPS $ 
Volume 3,036,099